These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
727 related articles for article (PubMed ID: 31122263)
1. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors. Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263 [TBL] [Abstract][Full Text] [Related]
2. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140 [TBL] [Abstract][Full Text] [Related]
3. FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage. Mancini M; Castagnetti F; Soverini S; Leo E; De Benedittis C; Gugliotta G; Rosti G; Bavaro L; De Santis S; Monaldi C; Martelli M; Santucci MA; Cavo M; Martinelli G J Cell Biochem; 2017 Nov; 118(11):3968-3975. PubMed ID: 28401599 [TBL] [Abstract][Full Text] [Related]
4. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia. Marsola APZC; Simões BP; Palma LC; Berzoti-Coelho MG; Burin SM; de Castro FA Med Oncol; 2018 Jan; 35(3):26. PubMed ID: 29387948 [TBL] [Abstract][Full Text] [Related]
5. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Dasmahapatra G; Patel H; Nguyen T; Attkisson E; Grant S Clin Cancer Res; 2013 Jan; 19(2):404-14. PubMed ID: 23204129 [TBL] [Abstract][Full Text] [Related]
6. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Jin B; Wang C; Li J; Du X; Ding K; Pan J Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973 [TBL] [Abstract][Full Text] [Related]
7. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells. Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884 [TBL] [Abstract][Full Text] [Related]
8. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. Balabanov S; Gontarewicz A; Keller G; Raddrizzani L; Braig M; Bosotti R; Moll J; Jost E; Barett C; Rohe I; Bokemeyer C; Holyoake TL; Brümmendorf TH PLoS One; 2011 Apr; 6(4):e19164. PubMed ID: 21541334 [TBL] [Abstract][Full Text] [Related]
9. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance. Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639 [TBL] [Abstract][Full Text] [Related]
10. Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model. Yuan H; Wang Z; Zhang H; Roth M; Bhatia R; Chen WY Carcinogenesis; 2012 Feb; 33(2):285-93. PubMed ID: 22116466 [TBL] [Abstract][Full Text] [Related]